Advertisement!
Author Information Pack
Editorial Board
Submit article
Special Issue
Editor's selection process
Join as Reviewer/Editor
List of Reviewer
Indexing Information
Most popular articles
Purchase Single Articles
Archive
Free Online Access
Current Issue
Recommend this journal to your library
Advertiser
Accepted Articles
Search Articles
Email Alerts
FAQ
Contact Us
Indian Journal of Cancer Education and Research

Volume  5, Issue 1, January - June 2017, Pages 29-35
 

Original Article

Clinical Profile and Therapy of Hepatocelluar Carcinoma at a Tertiary Care Institute from South India: A Retrospective Study of 182 Patients

Venkatesh M.*, Kannan T.**, Subbarao***, Bhargavi D.****, Ananth Pai****

*Senior Resident **Professor and Head ***Associate Professor ****Assistant Professor, Department of Medical Oncology, Sri Venkateswara Institute of Medical Sciences, Tirupati, India.

Choose an option to locate / access this Article:
90 days Access
Check if you have access through your login credentials.        PDF      |
|

Open Access: View PDF

DOI: DOI: http://dx.doi.org/10.21088/ijcer.2321.9815.5117.5

Abstract

Objective: To study the clinical profile and therapy of hepatocellular carcinoma (HCC) at a tertiary care institute in Andhrapradesh, Southindia. Methods: Data analysis of HCC patients enrolled in between 2000 and 2015. HCC was diagnosed according to EASL criteria-USG/CT/MRI of the abdomen and/or serum alpha-fetoprotein and/or histology (where indicated). Barcelona Clinic Liver Cancer (BCLC) staging was done. Results: We registered 182 HCC patients [males 162 (89%), mean age 57.5 ± 12.1 years]. An “Early Peak” (17%) was detected in 28-40 yr age group. The etiology of HCC was: Hepatitis B virus 70 (35.7%), Hepatitis C virus 05 (2.74%). Serum -fetoprotein was >500 ng/ml in 43.8% and very high (>5000-100 000) in 30.6%. Classical features on triple phase CT in 80% with an average tumor size of (7.3 ± 2.1 cm), Portal vein invasion was seen in 40% and distant metastases in 11%. Majority of the patients (79.6%) were BCLC stage C and D. Biochemical: Thrombocytopenia (60%), anaemia in 30%, and 80% had an elevated alkaline phosphatase levels. Therapy was offered to 127 (69.78%) patients.Treatment given was as follows: Surgical resection (n=36 19.78%); Chemotherapy, both oral and iv (n=91 19.78%), and Sorafenib (n=36 19.78%), Best supportive care (n=55 30.22%), but survival data was not available due to lack of adequate followup. Conclusions: Hepatitis B infection is the predominant cause for HCC. Diagnostic range serum -fetoprotein was detected in only 43.8% of study patients but its level correlates well with the disease burden, outcome. An “Early Peak” was observed in 28-40 year age group. Majority of the patients present with advanced disease, precluding the curative therapies. Universal immunization with hepatitis B vaccination will reduce the HBV infection rates & in part HCC burden in near future.

Keywords: HCC (Hepatocellular Carcinoma); AFP (Alpha Fetoprotein); HBV (Hepatitis B Virus).


Corresponding Author : Venkatesh M.*